| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Obstetrics and Gynecology [T. R., C. H., D. R., B. G., K. F.], Institute of Immunology [D. Ko., H-J. T.], University of Rostock, 18055 Rostock, and Department of Immunology, Paul-Ehrlich-Institute, 63225 Langen [D. Ka.], Germany
Programmed cell death (apoptosis) is primarily mediated by Fas ligand (FasL; CD95L) and the Fas receptor (Fas; CD95). In this study, FasL was detected by immunohistochemical analysis in 85% of breast carcinomas and 14% of fibroadenomas randomly chosen, indicating that high expression of FasL might play a role in tumor pathology. FasL and Fas levels as well as FasL:Fas ratios were further ascertained in 215 human breast tumors, including 199 invasive ductal carcinomas, by real-time quantitative reverse transcription-PCR and compared with expression levels and ratios found in 25 normal human tissues, in 37 fibroadenomas, and in 5 normal breast tissues. Among breast carcinomas, high FasL mRNA expression seems to be positively correlated with histological grading (n = 212; P < 0.0001). A ratio of FasL:Fas mRNA transcripts >1 is found to be significantly associated with decreased patient’s disease-free survival (n = 211; P < 0.03) and increased mortality (n = 211; P = 0.19). A FasL:Fas ratio >1 is related to tumor progression scored by histological grading (n = 212; P < 0.02). The selection process leading to highly aggressive breast tumor variants might be enhanced by FasL-mediated tumor fratricide, eventually a possible target for novel therapeutic strategies.
This article has been cited by other articles:
|
|
 |
|
  V. Minas, U. Jeschke, S.N. Kalantaridou, D.U. Richter, T. Reimer, I. Mylonas, K. Friese, and A. Makrigiannakis Abortion is associated with increased expression of FasL in decidual leukocytes and apoptosis of extravillous trophoblasts: a role for CRH and urocortin Mol. Hum. Reprod., September 1, 2007; 13(9): 663 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhang, T. Sun, L. Xue, X. Han, B. Zhang, N. Lu, Y. Shi, W. Tan, Y. Zhou, D. Zhao, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer Carcinogenesis, May 1, 2007; 28(5): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bohana-Kashtan and C. I. Civin Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity? Clin. Cancer Res., February 1, 2005; 11(3): 968 - 970. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes Cancer Res., September 15, 2004; 64(18): 6775 - 6782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Botti, S. Buglioni, M. Benevolo, D. Giannarelli, P. Papaldo, F. Cognetti, P. Vici, F. Di Filippo, F. Del Nonno, F. M. Venanzi, et al. Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy Clin. Cancer Res., February 15, 2004; 10(4): 1360 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rajesh, R. A. Stenzel, and S. P. Howard Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma J. Biol. Chem., September 19, 2003; 278(38): 35968 - 35978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Andreola, L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P. Accornero, F. Lozupone, L. Lugini, et al. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles J. Exp. Med., May 20, 2002; 195(10): 1303 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sjostrom, C. Blomqvist, K. von Boguslawski, N.-O. Bengtsson, I. Mjaaland, P. Malmstrom, B. Ostenstadt, E. Wist, V. Valvere, S. Takayama, et al. The Predictive Value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for Chemotherapy Response in Advanced Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Masui, R. Hosotani, S. Tsuji, Y. Miyamoto, S. Yasuda, J. Ida, S. Nakajima, M. Kawaguchi, H. Kobayashi, M. Koizumi, et al. Expression of METH-1 and METH-2 in Pancreatic Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3437 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kunz, S. Ibrahim, D. Koczan, H.-J. Thiesen, H. J. Köhler, T. Acker, K. H. Plate, S. Ludwig, U. R. Rapp, E.-B. Bröcker, et al. Activation of c-Jun NH2-Terminal Kinase/Stress-activated Protein Kinase (JNK/SAPK) Is Critical for Hypoxia-induced Apoptosis of Human Malignant Melanoma Cell Growth Differ., March 1, 2001; 12(3): 137 - 145. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
